OncLive® On Air

S15 Ep42: Long-Term Epcoritamab Data Show Durable Responses and Confirmed Safety in LBCL: With Tycel Phillips, MD

S15 Ep41: Multidisciplinary Breast Cancer Experts Outline Proactive Strategies for Managing Treatment-Related Toxicities: With Neil Iyengar, MD; Heather Moore, CPP, PharmD; and Sarah Donahue, MPH, NP

S15 Ep40: ELEGANT Trial Seeks to Expand Treatment Options for ER+, HER2-Negative Early Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

S15 Ep39: Novel Targeted Agents Are Poised to Influence MPN Treatment Paradigm: With John O. Mascarenhas, MD

S15 Ep38: Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

S15 Ep37: Immuno-Oncology and Novel Cell Therapies Set Transformation in Motion for Gynecologic Oncology: With Ursula A. Matulonis, MD; and Rebecca Porter, MD, PhD

S15 Ep36: Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Integrating recent clinical trial data into breast cancer treatment requires balancing efficacy with long-term safety, particularly regarding interstitial lung disease. Destiny Breast 11 demonstrates that TDXD followed by THP significantly improves pathologic complete response in high-risk HER2-positive early-stage bre...

S15 Ep35: Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2– Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

S15 Ep34: Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

S15 Ep33: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

S15 Ep32: Lisaftoclax Plus Azacitidine May Make New Inroads in Higher-Risk MDS Management: With Guillermo Garcia-Manero, MD

S15 Ep31: Medical Crossfire® From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

S15 Ep30: Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Management of early-stage hormone receptor-positive HER2-negative breast cancer increasingly integrates CDK4-6 inhibitors, PARP inhibitors, and immune checkpoint inhibitors to improve long-term survival. Clinical trials like Monarch-E and NATALI demonstrate that adjuvant CDK4-6 inhibition provides a sustained invasive ...

S15 Ep29: Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy

S15 Ep28: Emerging CELMoDs Set New Standards for Efficacy and Tolerability in Myeloma: With Rahul Banerjee, MD, FACP

S15 Ep27: Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Personalizing first-line and maintenance therapy for HER2-positive metastatic breast cancer requires integrating data-driven strategies for hormone receptor-positive patients. The PATINA trial demonstrates that adding the CDK4/6 inhibitor palbociclib to maintenance endocrine and HER2-targeted therapy significantly impr...

S15 Ep26: FDA Approval Insights: Epcoritamab Plus Rituximab/Lenalidomide for Relapsed/Refractory Follicular Lymphoma: With Lorenzo Falchi, MD

S15 Ep25: FDA Approval Insights: BVd for Relapsed/Refractory Multiple Myeloma: With Surbhi Sidana, MD

S15 Ep24: PRRT With 177Lu-Edotreotide Improves Outcomes vs Everolimus in Metastatic GEP-NETs: With Jonathan R. Strosberg, MD

S15 Ep23: Experts Explore Intersections Between Breast Surgery and Radiation for Comprehensive Care: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD; and Valentina Bonev, MD, DABS, FACS, FSSO